SAN DIEGO, May 3, 2018 /PRNewswire/ -- OncoSec Medical
Incorporated (OncoSec) (NASDAQ:ONCS), a company developing
intratumoral cancer immunotherapies, today announced that
Daniel J. O'Connor, Chief Executive
Officer of OncoSec, will present at the Eighth Annual BioNJ
BioPartnering Conference, developed in partnership with J.P.
Morgan, being held Thursday, May 3,
2018 at the The Palace at Somerset Park in Somerset, NJ.
As part of his presentation, Mr. O'Connor will discuss OncoSec's
corporate growth strategy; provide a comprehensive overview of the
Company's ongoing and anticipated clinical programs involving
ImmunoPulse® IL-12 (or Intratumoral tavo-EP) in metastatic melanoma
and triple-negative breast cancer (TNBC); and the potential of
ImmunoPulse® IL-12 as a monotherapy and in combination with
anti-PD-1 antibody therapy in metastatic melanoma and
triple-negative breast cancer (TNBC). In addition to the
presentation, management will participate in one-on-one meetings
with qualified members of the investor community who are registered
to attend the conference.
BioNJ's Eighth Annual BioPartnering Conference, developed in
partnership with J.P. Morgan Chase, will bring together nearly 400
public and private company investors, life sciences professionals
and academic partners from the Northeast to Mid-Atlantic states.
Pharmaceutical sponsors for the conference include The Janssen
Pharmaceutical Companies of Johnson & Johnson, Merck, and
Pfizer.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse
is designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as plasmid encoded IL-12
(tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical
trials, ImmunoPulse® IL-12 has demonstrated a favorable
safety profile, evidence of anti-tumor activity in the treatment of
various solid tumors, and the potential to reach beyond the site of
local treatment to initiate a systemic immune response. OncoSec's
lead program, ImmunoPulse IL-12, is currently in clinical
development for metastatic melanoma and triple-negative breast
cancer. The program's current focus is on the significant unmet
medical need in patients with melanoma who are refractory or have
relapsed on anti-PD-1 therapies. In addition to tavo, the Company
is also identifying and developing new immune-targeting agents for
use with the ImmunoPulse platform. For more information, please
visit www.oncosec.com.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
Janine McCargo / David Schemelia
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
jmccargo@tiberend.com
dschemelia@tiberend.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-at-eighth-annual-bionj-biopartnering-conference-300641776.html
SOURCE OncoSec Medical Incorporated